Cancer Family
Genitourinary System Neoplasm
CI-CAN-00000018Explore in graph →
Non-malignant3,856 active trials61 approved drugs307 evidence items
- NCIt
- C156482
Loading cancer entity…
Cancer Family
CI-CAN-00000018Explore in graph →
Clinical trials
17,398 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00188539 | Cervix: Hypoxia, Interstitial Fluid Pressure and GSH Levels | active not recruiting | Phase 2 | 346 | University Health Network, TorontoOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT05295992 | Conventionally Fractionated Adaptive Radiation Therapy of Bladder Cancer an Individualized Approach(ARTIA-Vesica) | active not recruiting | N/A | 110 | Varian, a Siemens Healthineers CompanyINDUSTRY | 1 | Mar 6, 2026 |
| clinicaltrials |
| NCT01181375 | Predictive Assays In Cervix Cancer | active not recruiting | N/A | 500 | University Health Network, TorontoOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT01970722 | Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer | active not recruiting | Phase 1 | 40 | City of Hope Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT05122546 | CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer | active not recruiting | Phase 1 | 31 | City of Hope Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT05331638 | Prostate Cancer Genius App Education and Home-based PSA Screening for African American Men(PCGA) | active not recruiting | N/A | 80 | University of OklahomaOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT05364229 | MR-guided Tumour Boost(MRL-Boost PC) | active not recruiting | N/A | 40 | University Health Network, TorontoOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT06028932 | A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients | active not recruiting | Phase 2 | 20 | Yale UniversityOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT03938649 | SRAM study_Postate Cancer | active not recruiting | Phase 2 | 120 | CCTUOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT05154162 | PSMA PET Additive Value for Prostate Cancer Diagnosis in Men With Negative/Equivocal MRI(PRIMARY2) | active not recruiting | Phase 3 | 660 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT05546268 | Study of Oral MRT-2359 in Selected Cancer Patients | active not recruiting | Phase 1 / Phase 2 | 174 | Monte Rosa Therapeutics, IncINDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07431684 | Sense of Coherence and Quality of Life in Prostate Cancer Patients Treated With Radical Radiotherapy | active not recruiting | N/A | 250 | Institute of Oncology LjubljanaOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT02723734 | Validation Study on the Impact of Decipher® Testing - VANDAAM Study(VANDAAM) | active not recruiting | — | 240 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT04884360 | D9319C00001- 1L OC Mono Global RCT(MONO-OLA1) | active not recruiting | Phase 3 | 366 | AstraZenecaINDUSTRY | 10 | Mar 2, 2026 | clinicaltrials |
| NCT01684397 | Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer | active not recruiting | Phase 1 / Phase 2 | 51 | Roswell Park Cancer InstituteOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT03403465 | Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers | active not recruiting | Phase 2 | 90 | Duke UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04422132 | Randomized Phase II Trial of Salvage Radiotherapy for Prostate Cancer In 4 Weeks v. 2 Weeks | active not recruiting | Phase 2 | 134 | Weill Medical College of Cornell UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04742075 | Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer(DOVACC) | active not recruiting | Phase 2 | 188 | Nordic Society of Gynaecological Oncology - Clinical Trials UnitOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04943536 | Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer(BiolenRT) | active not recruiting | Phase 1 | 20 | Alessa Therapeutics Inc.INDUSTRY | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04969887 | Combination Immunotherapy in Rare Cancers Under InvesTigation(MOST-CIRCUIT) | active not recruiting | Phase 2 | 240 | Olivia Newton-John Cancer Research InstituteOTHER | 2 | Feb 27, 2026 | clinicaltrials |
| NCT06240598 | A Study of Second Look Laparoscopy (SLL) in People With Ovarian Cancer Who Have Completed Their First Course of Chemotherapy | active not recruiting | Phase 2 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT02296229 | Stereotactic Body Radiation Therapy in Treating Patients With Localized High-Risk Prostate Cancer | active not recruiting | N/A | 220 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT03016741 | Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer | active not recruiting | Phase 4 | 100 | Northwestern UniversityOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT05438420 | Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 120 | Qurient Co., Ltd.INDUSTRY | 2 | Feb 24, 2026 | clinicaltrials |
| NCT06964958 | 177LuPSMA in Renal Cell Carcinoma(LASER) | active not recruiting | Phase 2 | 24 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT02307058 | Randomized MRI-Guided Prostate Boosts Via Initial Lattice Stereotactic vs Daily Moderately Hypofractionated Radiotherapy(BLaStM) | active not recruiting | N/A | 164 | University of MiamiOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT02353819 | Stereotactic Ablative Radiotherapy (SABR) of Pelvis and Prostate Targets For High Risk Prostate Cancer | active not recruiting | Phase 1 | 60 | University of Texas Southwestern Medical CenterOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT02811861 | Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma(CLEAR) | active not recruiting | Phase 3 | 1,069 | Eisai Inc.INDUSTRY | 20 | Feb 23, 2026 | clinicaltrials |
| NCT03089203 | CART-PSMA-TGFβRDN Cells for Castrate-Resistant Prostate Cancer | active not recruiting | Phase 1 | 23 | University of PennsylvaniaOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT04258462 | Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors | active not recruiting | Phase 2 | 54 | Zhen Wang, MDOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT06037863 | Evaluation of the Impact of Empty Versus Full Bladder in Patients With Prostate Cancer, RELIEF Trial | active not recruiting | N/A | 168 | Mayo ClinicOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT03334500 | Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Prostate Cancer | active not recruiting | Early Phase 1 | 30 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT04258813 | Onco-primary Care Networking to Support TEAM-based Care(ONE TEAM) | active not recruiting | N/A | 313 | Duke UniversityOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT05527184 | First in Human Study of IMGN151 in Recurrent Gynaecological Cancers | active not recruiting | Phase 1 | 256 | AbbVieINDUSTRY | 10 | Feb 20, 2026 | clinicaltrials |
| NCT03252938 | Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors(INSIGHT) | active not recruiting | Phase 1 | 83 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT04848519 | Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma | active not recruiting | Phase 2 | 6 | Emory UniversityOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT05668351 | Stereotactic Ablative Radiation Therapy for Prostate Cancer(SUPR-SABR) | active not recruiting | N/A | 42 | Medical University of South CarolinaOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT06483334 | A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04) | active not recruiting | Phase 1 / Phase 2 | 38 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Feb 18, 2026 | clinicaltrials |
| NCT03045965 | Hysterectomy and OPPortunistic SAlpingectomy(HOPPSA) | active not recruiting | N/A | 4,400 | Göteborg UniversityOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT03520491 | A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy | active not recruiting | Phase 2 | 52 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT03771651 | Short Term Aspirin on the Biologic and Immunologic Changes of the Fallopian Tube | active not recruiting | Early Phase 1 | 18 | University of OklahomaOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT05656976 | Efficacy of Offering a Self-sampling Device by the GP to Reach Underscreened Women(ESSAG) | active not recruiting | N/A | 3,375 | University GhentOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT04081428 | Using Breath, Cell Free DNA and Image Analysis to PRedIct Normal TissUe and Tumour Response During Prostate Cancer SBRT(PRINToUT) | active not recruiting | — | 60 | NHS LothianOTHER_GOV | 1 | Feb 13, 2026 | clinicaltrials |
| NCT05683964 | Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression | active not recruiting | Early Phase 1 | 9 | Beth Israel Deaconess Medical CenterOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT04754191 | Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer(ENCORE) | active not recruiting | Phase 2 | 34 | University of UtahOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT05160597 | Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy | active not recruiting | Early Phase 1 | 30 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT05316181 | CRS & HIPEC for Platinum-Resistant Recurrent Ovarian Cancer (KOV-02R, RECOVER)(KOV-HIPEC-02R) | active not recruiting | Phase 3 | 140 | National Cancer Center, KoreaOTHER_GOV | 1 | Feb 12, 2026 | clinicaltrials |
| NCT05320406 | RElugolix VErsus LeUprolide Cardiac Trial(REVELUTION) | active not recruiting | Phase 2 | 94 | Emory UniversityOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT04781088 | Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 2 | 38 | Floor Backes, MDOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT06627530 | COACTION Trial - COmbination Androgen bloCkade in inTermediate to hIgh-risk prOstate caNcer(COAction) | active not recruiting | Phase 4 | 144 | Brazilian Clinical Research InstituteOTHER | 1 | Feb 11, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Mar 6, 2026source: clinicaltrials